A new device to improve inhaled drug delivery for pulmonary hypertension
Novel Device to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment
This study is testing a new nebulizer that changes how it delivers medicine based on how you breathe, making it easier for people with pulmonary hypertension, especially older adults, to get their treatments and feel better.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bridgesource Medical Corporation NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10912642 on NIH RePORTER |
What this research studies
This research focuses on developing a breath-adaptive nebulizer that can deliver aerosolized medications more effectively for patients with pulmonary hypertension. The device will adjust the size of aerosol droplets and the timing of drug delivery based on the patient's breathing patterns, making it easier for patients, especially the elderly, to receive their medications. By improving the efficiency of drug delivery, this device aims to enhance treatment compliance and outcomes for individuals with respiratory conditions. The ultimate goal is to create a device that can be approved by the FDA for clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with pulmonary hypertension, particularly elderly individuals who struggle with traditional inhalation therapies.
Not a fit: Patients with mild respiratory conditions or those who do not require aerosolized medication may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and user-friendly method of delivering medications for patients with pulmonary hypertension.
How similar studies have performed: Other research has shown promise in improving aerosol delivery systems, but this specific approach with a breath-adaptive nebulizer is relatively novel.
Where this research is happening
Austin, United States
- Bridgesource Medical Corporation — Austin, United States (Active)
Researchers
- Principal investigator: Porterfield, John E — Bridgesource Medical Corporation
- Study coordinator: Porterfield, John E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.